Around 7,500 women are diagnosed with high-grade serious ovarian cancer every year
The partial hold is based on the serious bleeding events reported in the safety analysis
The research was conducted under a partnership with BCI Pharma
Nearly half of the women treated with avutometinib and defactinib saw their tumours shrink significantly, results show
The trial is set to run in Walsall, Sandwell and Birmingham for 18 months
Only one in two women were able to recognise persistent pain and bloating as signs of ovarian cancer in new survey
Ovarian cancer is the second most common gynaecologic cancer in the US
